CORCEPT THERAPEUTICS INC Total Liabilities and Equity
CORCEPT THERAPEUTICS INC (CORT) had Total Liabilities and Equity of $888.70 million as of 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-07-29
- 2026-06-30: Liabilities and Equity $888.70M.
- 2026-03-31: Liabilities and Equity $814.88M.
- 2025-12-31: Liabilities and Equity $836.65M.
- 2025-09-30: Liabilities and Equity $823.61M.
| Period end | Liabilities and Equity | Liabilities and Equity as first filed |
|---|---|---|
| 2026-06-30 | $888.70M 10-Q · filed 2026-07-29 | |
| 2026-03-31 | $814.88M 10-Q · filed 2026-04-30 | |
| 2025-12-31 | $836.65M 10-Q · filed 2026-07-29 | |
| 2025-09-30 | $823.61M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $801.72M 10-Q · filed 2025-07-31 | |
| 2025-03-31 | $846.46M 10-Q · filed 2025-05-05 | |
| 2024-12-31 | $840.55M 10-K · filed 2026-02-24 | |
| 2024-09-30 | $784.26M 10-Q · filed 2024-10-30 | |
| 2024-06-30 | $714.55M 10-Q · filed 2024-07-29 | |
| 2024-03-31 | $655.93M 10-Q · filed 2024-05-01 | |
| 2023-12-31 | $621.52M 10-K · filed 2025-02-26 | |
| 2023-09-30 | $594.02M 10-Q · filed 2023-11-01 | |
| 2023-06-30 | $524.63M 10-Q · filed 2023-08-02 | |
| 2023-03-31 | $617.85M 10-Q · filed 2023-05-03 | |
| 2022-12-31 | $583.43M 10-K · filed 2024-02-15 | |
| 2022-09-30 | $533.25M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $496.36M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $468.12M 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $423.76M 10-K · filed 2023-02-28 | |
| 2021-09-30 | $585.40M 10-Q · filed 2021-11-03 | |
| 2021-06-30 | $568.48M 10-Q · filed 2021-07-29 | |
| 2021-03-31 | $552.40M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $571.73M 10-K · filed 2022-02-15 | |
| 2020-09-30 | $534.13M 10-Q · filed 2020-11-03 | |
| 2020-06-30 | $497.82M 10-Q · filed 2020-08-04 | |
| 2020-03-31 | $445.49M 10-Q · filed 2020-05-04 | |
| 2019-12-31 | $412.31M 10-K · filed 2021-02-23 | |
| 2019-09-30 | $367.02M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $328.68M 10-Q · filed 2019-08-01 | |
| 2019-03-31 | $320.21M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $311.69M 10-K · filed 2020-02-24 | |
| 2018-09-30 | $299.75M 10-Q · filed 2018-11-02 | |
| 2018-06-30 | $274.38M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $242.98M 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $220.54M 10-K · filed 2019-02-26 | |
| 2017-09-30 | $110.67M 10-Q · filed 2017-11-03 | |
| 2017-06-30 | $86.54M 10-Q · filed 2017-08-02 | |
| 2017-03-31 | $75.34M 10-Q · filed 2017-05-02 | |
| 2016-12-31 | $68.75M 10-K · filed 2018-02-28 | |
| 2016-09-30 | $62.93M 10-Q · filed 2016-11-02 | |
| 2016-06-30 | $56.84M 10-Q · filed 2016-08-03 | |
| 2016-03-31 | $52.91M 10-Q · filed 2016-05-04 | |
| 2015-12-31 | $51.90M 10-K · filed 2017-03-06 | $51.94M 10-K · filed 2016-03-10 |
| 2015-09-30 | $48.38M 10-Q · filed 2015-11-06 | |
| 2015-06-30 | $48.35M 10-Q · filed 2015-08-07 | |
| 2015-03-31 | $48.22M 10-Q · filed 2015-05-08 | |
| 2014-12-31 | $34.63M 10-K · filed 2016-03-10 | |
| 2014-09-30 | $37.16M 10-Q · filed 2014-11-07 | |
| 2014-06-30 | $44.39M 10-Q · filed 2014-08-08 | |
| 2014-03-31 | $52.83M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | $63.08M 10-K · filed 2015-03-13 | |
| 2013-09-30 | $71.06M 10-Q · filed 2013-11-12 | |
| 2013-06-30 | $79.69M 10-Q · filed 2013-08-09 | |
| 2013-03-31 | $88.14M 10-Q · filed 2013-05-08 | |
| 2012-12-31 | $99.17M 10-K · filed 2014-03-14 | |
| 2012-09-30 | $105.52M 10-Q · filed 2012-11-08 | |
| 2012-06-30 | $38.62M 10-Q · filed 2012-08-09 | |
| 2012-03-31 | $42.89M 10-Q · filed 2012-05-10 | |
| 2011-12-31 | $39.83M 10-K · filed 2013-03-15 | |
| 2011-09-30 | $46.38M 10-Q · filed 2011-11-08 | |
| 2011-06-30 | $52.72M 10-Q · filed 2011-08-09 | |
| 2010-12-31 | $25.10M 10-K · filed 2012-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |